SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Rationally targeted therapies have transformed cancer treatment, but many patients develop resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an allosteric SHP2 inhibitor designed to overcome bypass-signaling-mediated resistance when combined with inhibitors of various...

Descripción completa

Detalles Bibliográficos
Autores principales: Drilon, Alexander, Sharma, Manish R., Johnson, Melissa L., Yap, Timothy A., Gadgeel, Shirish, Nepert, Dale, Feng, Gang, Reddy, Micaela B., Harney, Allison S., Elsayed, Mohamed, Cook, Adam W., Wong, Christina E., Hinklin, Ronald J., Jiang, Yutong, Brown, Eric N., Neitzel, Nickolas A., Laird, Ellen R., Wu, Wen-I, Singh, Anurag, Wei, Ping, Ching, Keith A., Gaudino, John J., Lee, Patrice A., Hartley, Dylan P., Rothenberg, S. Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401072/
https://www.ncbi.nlm.nih.gov/pubmed/37269335
http://dx.doi.org/10.1158/2159-8290.CD-23-0361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401072/
https://www.ncbi.nlm.nih.gov/pubmed/37269335
http://dx.doi.org/10.1158/2159-8290.CD-23-0361

Ejemplares similares